LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
26 funds hold it · 3 straight earnings beats
No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 29, 2026
Period ending
Sep 30, 2026
Earnings per share
$0.52 expected
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 29, 2026 | $0.58est. $0.52 | +11.92%beat | $2.98BSEC filing | +5.0%from $2.83B |
| Jun 30, 2026Reported Jul 30, 2026 | $0.56est. $0.37 | +52.53%beat | $2.96BSEC filing | +5.3%from $2.81B |
| Mar 31, 2026Reported Apr 30, 2026 | $0.36est. $0.31 | +15.93%beat | $2.70BSEC filing | +2.9%from $2.63B |
| Dec 31, 2025Reported Feb 12, 2026 | $0.44est. $0.54 | -17.80%miss | $2.97BAlpha Vantage | +8.0%from $2.75B |
| Sep 30, 2025Reported Oct 30, 2025 | $0.69est. $0.60 | +15.00%beat | $2.83BSEC filing | +5.0%from $2.70B |
| Jun 30, 2025Reported Jul 31, 2025 | $0.59est. $0.61 | -3.28%miss | $2.81BSEC filing | +4.3%from $2.69B |
| Mar 31, 2025Reported May 1, 2025 | $0.55est. $0.48 | +14.58%beat | $2.63BSEC filing | +5.4%from $2.49B |
| Dec 31, 2024Reported Feb 20, 2025 | $0.58est. $0.52 | +11.54%beat | $2.75BSEC filing | +0.9%from $2.73B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $2.97B | $2.70B | $2.96B | $2.98B |
| Cost of what it sold | $2.40B | $1.81B | $1.93B | $1.98B |
| Gross profit | $577.0M | $891.0M | $1.03B | $994.0M |
| What it spent | ||||
| Research and development | $126.0M | $139.0M | $129.0M | $125.0M |
| Sales and admin | $761.0M | $728.0M | $735.0M | $730.0M |
| Other operating costs | $419.0M | -$42.0M | -$49.0M | -$86.0M |
| Total operating expenses | $1.31B | $825.0M | $815.0M | $769.0M |
| What was left | ||||
| Operating profit | -$729.0M | $66.0M | $217.0M | $225.0M |
| Interest on debt | $69.0M | $78.0M | $77.0M | $61.0M |
| Profit before tax | -$756.0M | -$6.0M | $158.0M | $417.0M |
| Tax | $279.0M | $11.0M | $23.0M | $119.0M |
| Net profit | -$1.13B | -$15.0M | $126.0M | $294.0M |
| EBITDA | -$447.0M | $297.0M | $474.0M | $478.0M |
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Former Medtronic and Baxter International Executives Join Chapman & Co. Leadership Institute, Expanding Healthcare and MedTech Expertise
Leans bullishNov 12City Therapeutics doses first participant in phase 1 trial of RNAi therapy CITY-RBP4 for Stargardt disease
Leans bullishNov 12Chapman & Co. Adds Former Medtronic, Baxter Executives
Leans bullishNov 12Washington Sues Major Dialysis Providers Over Noncompete Agreements
NeutralNov 10Sensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial Milestone
Leans bullishNov 10CoreCivic EVP Anthony L. Grande Sells 25,000 Shares at $31.49 on November 10, 2026
NeutralNov 10Orthofix Q3 Revenue Misses Estimates by $2.62 Million as EPS Beats
Leans bearishNov 10PR News | JF, FTI Work $6B Healthcare Deal - Mon., Nov. 9, 2026
Leans bullishNov 911 macro signals shaping BAX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
